Martin Shkreli Is At It Again, Refuses To Lower Price Of $750 Drug

The Turing Pharmaceuticals CEO promised to lower the drug price after hiking it up when his company acquired it. But it seems that isn't happening.
SMS
Martin Shkreli Is At It Again, Refuses To Lower Price Of $750 Drug

Remember Martin Shkreli, arguably the most hated man in pharmaceuticals for raising the cost of a drug HIV patients regularly take by 5,000 percent? Well, he's getting some very unwanted attention again.

Shkreli is the Turing Pharmaceuticals CEO who inflated the cost of the parasite-fighting and lifesaving drug Daraprim from $13.50 to $750. 

Patients, the medical community and the media blasted Shkreli for the move, and eventually he did say he'd reverse the price increase.

But on Wednesday his company said in a press release that it would drop prices by 50 percent for hospitals, create smaller bottles with 30 pills and provide free starter packs in 2016. The company also said, "We pledge that no patient needing Daraprim will ever be denied access." 

Sounds nice, right? Well, these changes might only affect bulk buys, since it seems as if the $750 price per pill is unchanged. 

Shkreli previously said the company needed to increase the pill's price so it could do studies to improve the drug. But critics have questioned his company's ability to do sound scientific research.

Some presidential hopefuls have even used Shkreli and Turing as a part of their platforms for health care or a conversation about how they could regulate the pharmaceutical industry to avoid price hikes like these in the future.

This video includes an image from the U.S. National Library of Medicine.

Featured Stories
Then-Labor Secretary Thomas Perez addresses the 10th annual Make Progress National Summit

Democrats Vote For Tom Perez To Make Their Party Great Again

People watch election returns

The New Democratic Party Chair Has A Tall Task Ahead

Trump in Oval Office

Leaked Government Document Seems To Be At Odds With Trump's Travel Ban

Want to see more stories like this?
Like Newsy on Facebook for More Medicine Coverage